ReviewThe New England journal of medicine2017
Sickle Cell Disease.
7 registry-linked trialsAbstract readReview
In one paragraph
Review in The New England journal of medicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 7 registered trials, which are not on this map. Cited by 677 papers, 6 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
677citing papers in PubMed, 6 pooled it
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Closely Matched Unrelated Donor Peripheral Blood Stem Cell Transplantation With TCRαβ+ T Cell and B Cell Depletion For Patients With Sickle Cell Disease and Thalassemia Major
A Phase 1 Randomized, Double-Blind, Placebo-Controlled, Single-and Multiple-Dose Study Evaluating Safety, Tolerability, and Pharmacokinetics, With an Open-Label Initial Food Effect and CYP3A Drug-Drug Interaction Study, of FTX-6058 in Healthy Adult Subjects, and a Randomized, Double-Blind, Placebo-Controlled Multiple-Dose Study Evaluating, Safety, Tolerability and Pharmacokinetics in Subjects With Sickle Cell Disease (SCD)
A Phase 1 Open-Label, Multiple-Dose Study to Evaluate Safety and Tolerability, Pharmacokinetics and Pharmacodynamics of FTX-6058 in Subjects With Sickle Cell Disease (SCD)
Single-center Pilot Study: Nano-rheological Biomarkers for Patients With Sickle Cell Disease (SCD) Versus Control Subjects (Other Constitutional Red Blood Cell Diseases and Healthy Subjects)
Aerobic Physical Fitness and Health-related Quality of Life in Children With Sickle Cell Disease.
Early Identification and Intervention Of Developmental Delay Among Infants And Toddlers With Sickle Cell Disease Using the Sickle Cell Caregiver Collaboration for Child Development (SCCCD) Intervention
NCT06989567 phase3not yet recruitingnot on this mapstarted 2025, after this paper: background citation
A Phase III, Multi-Center, Double-Blind, Placebo-Controlled, Randomized Study of Intravenous L-Citrulline in Sickle Cell Disease Presenting to Emergency Departments in Acute Vaso-Occlusive Crisis in Children, Adolescents and Young Adults (6 to 21 Years)
Who cites it
677 citing papers in PubMed, 6 syntheses or guidelines pooled it.
- Is There a Difference in Occurrence of Complications Between Adults With Hemoglobin SS and Hemoglobin SC Disease: An Extended Systematic Review.European journal of haematology · 2026Pooled it
- Global burden of moyamoya syndrome in pediatric sickle cell disease and implications for the neurosurgical workforce: a systematic review.Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery · 2026Pooled it
- Mortality Associated with Intensive Care Unit Admission and Mechanical Ventilation in Adults with Acute Chest Syndrome: A Systematic Review.Medicina (Kaunas, Lithuania) · 2026Pooled it
- Does Sickle Cell Anaemia Have a Relationship With Avascular Pulp Necrosis? A Systematic Review.Australian endodontic journal : the journal of the Australian Society of Endodontology Inc · 2026Pooled it
- Position statement on the management of pregnancy in sickle cell disease.The Australian & New Zealand journal of obstetrics & gynaecology · 2025Guideline
- COVID-19 outcomes among patients with sickle cell disease or sickle cell trait compared to the general population: a systematic review and meta-analyses.Annals of hematology · 2024Pooled it
- Clinical outcomes of lentiviral vector gene therapy for sickle cell disease.Blood advances · 2026Trial
- The acceptability and feasibility of a randomised controlled trial of serial prophylactic exchange blood transfusion versus usual care in pregnant women with sickle cell disease: a qualitative study.BMC pregnancy and childbirth · 2026Trial
- Improvements in health-related quality of life in patients with severe sickle cell disease after exagamglogene autotemcel.Blood advances · 2025Trial
- Haploidentical Bone Marrow Transplantation for Sickle Cell Disease.NEJM evidence · 2025Trial
- Real-World Evidence of Crizanlizumab Showing Reductions in Vaso-Occlusive Crises and Opioid Usage in Sickle Cell Disease.European journal of haematology · 2025Trial
- Kidney failure risk equation and early renal risk in adults with sickle cell disease: comparison with KDIGO classification using measured GFR.Renal failure · 2026Article
- "Does the dose of hydroxyurea correlate with shorter hospital stay and higher fetal hemoglobin levels in patients with sickle cell disease?"Future science OA · 2026Article
- Disease-associated mutations directionally modulate epigenetic age in iPSC-derived tissues.bioRxiv : the preprint server for biology · 2026Article
- Population-Stratified Human Genetic Studies Are Not Eugenics: A Response to Donohue and Myles.Bioethics · 2026Article
- A Multicenter, Open-Label, Phase 2 Trial Comparing Crizanlizumab Combined With Standard Therapy to Standard Therapy Alone on Renal Function in Patients With Sickle Cell Nephropathy (STEADFAST).American journal of hematology · 2026Article
- Emerging preclinical evidence supports a potential role for cannabidiol in the management of sickle cell disease.Haematologica · 2026Review
- Systemic delivery of phagocytosis-shielded retroviral vectors enables in vivo HSC gene therapy for sickle cell disease.Cell stem cell · 2026Article
- A global survey of blood transfusion practices for patients with sickle cell disease.Transfusion · 2026Article
- Prevalence and determinants of early markers of kidney damage in homozygotic sickle cell patients in the DR Congo: Update.Pediatric nephrology (Berlin, Germany) · 2026Article
617 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
- Commented on by
- Commented on by
- Commented on by
Authors and funding
3 authors.
Frédéric B PielFrom the Department of Epidemiology and Biostatistics, Medical Research Council-Public Health England (MRC-PHE) Centre for Environment and Health, School of Public Health, Imperial College London (F.B.P.), and the Department of Haematological Medicine, King's College Hospital, King's College London (D.C.R.), London; and the Department of Medicine, Boston University School of Medicine, Boston (M.H.S.).
Martin H SteinbergFrom the Department of Epidemiology and Biostatistics, Medical Research Council-Public Health England (MRC-PHE) Centre for Environment and Health, School of Public Health, Imperial College London (F.B.P.), and the Department of Haematological Medicine, King's College Hospital, King's College London (D.C.R.), London; and the Department of Medicine, Boston University School of Medicine, Boston (M.H.S.).
David C ReesFrom the Department of Epidemiology and Biostatistics, Medical Research Council-Public Health England (MRC-PHE) Centre for Environment and Health, School of Public Health, Imperial College London (F.B.P.), and the Department of Haematological Medicine, King's College Hospital, King's College London (D.C.R.), London; and the Department of Medicine, Boston University School of Medicine, Boston (M.H.S.).
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Anemia, Sickle CellAir Pollutionalpha-ThalassemiaFetal HemoglobinHumansInfant, NewbornInfectionsPhenotypeFetal Hemoglobin
Identifiers
PMID
28423290What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
NCT04523376ClinicalTrials.gov
NCT04586985ClinicalTrials.gov
NCT05169580ClinicalTrials.gov
NCT05530239ClinicalTrials.gov
NCT05995743ClinicalTrials.gov
NCT06562439ClinicalTrials.gov
and 1 more above
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.